Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Nicolas Williet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7296-5464; OpenAlex author ID A5070672619. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper, 1 trial · 2021: 6 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 3 papers

Papers 20

  1. Impact of preoperative muscle mass deficit and myosteatosis on postoperative short-term outcomes after esophageal or pancreatic cancer surgery. Co-author DOI 10.1016/j.clnesp.2026.103406↗
  2. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Co-author DOI 10.1016/j.dld.2026.10.006↗
  3. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  4. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  5. Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). Co-author DOI 10.1016/j.esmogo.2025.100142↗
  6. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  7. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  8. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  9. Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN). Co-author DOI 10.1016/j.pan.2023.06.010↗
  10. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  11. Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. Co-author DOI 10.3390/cancers14215413↗
  12. Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00432-021-03590-x↗
  13. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  14. A Low Total Psoas Muscle Area Index Is a Strong Prognostic Factor in Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001796↗
  15. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. First author DOI 10.1200/jco.20.03329↗
  16. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Co-author DOI 10.3390/cancers13112797↗
  17. Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database. Co-author DOI 10.3390/cancers13143515↗
  18. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … Co-author DOI 10.1016/j.clinre.2019.08.009↗
  19. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
  20. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗

Trials 1

  1. SERum-bank for PANcreatic Cancer Principal investigator NCT04374175↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olivier Bouché · 8 shared papers, 2018–2026 · strength 1.28
  2. Jean‐Baptiste Bachet · 8 shared papers, 2018–2026 · strength 1.24
  3. Gaël S. Roth · 7 shared papers, 2021–2026 · strength 1.19
  4. David Tougeron · 7 shared papers, 2019–2025 · strength 0.94
  5. Camille Evrard · 5 shared papers, 2022–2026 · strength 0.87
  6. Anthony Turpin · 5 shared papers, 2021–2026 · strength 0.79
  7. Jean–Marc Phelip · 6 shared papers, 2019–2025 · strength 0.74
  8. Cindy Neuzillet · 4 shared papers, 2018–2026 · strength 0.68
  9. Julien Taı̈eb · 6 shared papers, 2018–2025 · strength 0.61
  10. Mathias Brügel · 3 shared papers, 2022–2025 · strength 0.51
  11. Christelle de la Fouchardière · 4 shared papers, 2021–2024 · strength 0.47
  12. Brice Chanez · 2 shared papers, 2025–2026 · strength 0.46
  13. Pascal R. Hammel · 3 shared papers, 2018–2025 · strength 0.44
  14. Jerome F. Cros · 2 shared papers, 2025–2026 · strength 0.42
  15. Jérôme MOREL · 1 shared paper, 2026 · strength 0.33
  16. Nory Elhadjène · 1 shared paper, 2026 · strength 0.33
  17. Anne‐Laure Pointet · 3 shared papers, 2019–2025 · strength 0.33
  18. Isabelle Trouilloud · 3 shared papers, 2019–2025 · strength 0.33
  19. Dominique Béchade · 3 shared papers, 2019–2025 · strength 0.33
  20. Simon Pernot · 3 shared papers, 2019–2025 · strength 0.33
  21. Laëtitia Dahan · 3 shared papers, 2018–2025 · strength 0.33
  22. Lysiane Marthey · 3 shared papers, 2018–2025 · strength 0.32
  23. Christelle d’Engremont · 2 shared papers, 2022–2026 · strength 0.31
  24. Xavier Roblin · 2 shared papers, 2021 · strength 0.28
  25. Louis de Mestier · 2 shared papers, 2018–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.